Pioneers in early and reliable Alzheimer's disease diagnostics

The cerebrospinal fluid (CSF) biomarkers, that were first developed by Fujirebio more than 25 years ago, have evolved over time from research biomarkers into specialized diagnostic testing tools, and from manual usage by early adopters to a widespread implementation in fully automated routine testing today.

Diagnosis for Alzheimer’s disease using CSF samples allows the detection of four proteins: two forms of amyloid (Aβ1-42 and Aβ1-40) proteins and two forms of Tau (Total Tau and phospho-Tau) proteins. If a patient has Alzheimer’s disease, then these proteins will be present in abnormally low (Aβ1-42 and Aβ1-42/Aβ1-40 ratio) and high (Total Tau and phospho-Tau) levels. The Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio will even be low long before the symptoms of the disease start to show.

In the clinical community today, there are high hopes for the use of blood-based testing for even simpler and potentially more widespread testing for Alzheimer’s disease in clinical routine. Plasma-based biomarkers for the two amyloid (Aβ1-42 and Aβ1-40) proteins and for the phospho-Tau protein are already available from Fujirebio for fully automated testing (for research use only). But research continues at the Fujirebio Neuro Center of Excellence, having led, for example, to the release of new assays for two promising biomarkers, NPTX2 and sTREM2, both for research use only.

This page collects resources and information about how Fujirebio contributes and collaborates closely with the international clinical community and partner organizations to develop the neurodegeneration diagnostic tools of the future.

 
Daniel and Sophia's story about living with Alzheimer's disease

In this video we follow Daniel and Sophia from Sweden. Daniel was diagnosed with Alzheimer's disease when he was still in his early 50's. He and his wife share their story from the first suspicion, the early diagnosis and how they and the family live with the disease. And their hopes for the future.

 

 

1. World Alzheimer Report 2015

 
Read more about our engagement in advancing Alzheimer's disease testing below
 or contact us today
 

Insights

Did you already read our popular clinical booklet?

Download the latest edition of our clinical booklet giving a detailed overview of the current state and challenges of early Alzheimer's disease diagnostics

Download booklet

Webinars

Webinar (01:04:39)

Webinar replay - Possible applications for novel CSF biomarkers

Webinar (01:04:09)

Webinar replay - Preparing for the future of plasma based Alzheimers disease diagnostics

Webinar (00:50:09)

Webinar replay - CSF-based biomarkers to support the diagnosis of Alzheimer’s disease

Did you already read our popular clinical booklet?

Download the latest edition of our clinical booklet giving a detailed overview of the current state and challenges of early Alzheimer's disease diagnostics

Download booklet